FDA OKs Dako Denmark genetic breast cancer test

01/14/2008 | Yahoo!

The FDA has approved a genetic test developed by Dako Denmark A/S designed to predict tumor recurrence and overall survival in breast cancer patients who are at higher risk of relapse. The test, which uses fluorescent probes to monitor the activity of genes that might play a role in tumor activity, could help doctors in providing additional treatment, the agency said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care